(1) Background: Although current guidelines recommend regular lipid testing for dyslipidemia patients, the effectiveness of regular lipid profile monitoring in clinical outcomes is unclear. (2) Methods: We assessed 64,664 newly diagnosed dyslipidemia patients from the Korean National Health Insurance Service Health Screening Cohort from 2003–2011 For lipid-testing frequency from all admission and outpatient records for 3 years after diagnosis. Participants were followed until 31 December 2015 for stroke. We used Cox regression analysis to determine the adjusted hazard ratio (aHR) for stroke according to lipid-testing interval. (3) Results: Compared to patients with lipid-testing intervals of ≤6 months, patients with >6 to ≤12 (aHR 1.32, 95% confidence interval (CI) 1.08–1.61), >12 to ≤18 (aHR 1.48, 95% CI 1.20–1.82), and >18 (aHR 1.54, 95% CI 1.25–1.90) month testing intervals had elevated risk of total stroke (p
for trend <0.001). A significant association existed between lipid-testing interval and total and ischemic stroke risk in the >6 to ≤12 (aHR 1.62, 95% CI 1.19–2.21), >12 to ≤18 (aHR 1.87, 95% CI 1.36–2.58), and >18 (aHR 1.79, 95% CI 1.30–2.48) month interval groups, but no significant association existed between lipid-testing interval and hemorrhagic stroke risk. (4) Conclusions: Lipid-testing intervals of more than 6 months may lead to increased stroke risk among newly diagnosed dyslipidemia patients after initiation of statin treatment. Lipid testing every 6 months can lower stroke risk among dyslipidemia patients.
This is an open access article distributed under the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited